Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future.
Recent trials, and meta-analyses, have cast further doubt on the clinically desirable and safe range for increasing haemoglobin in chronic kidney disease using erythropoiesis-stimulating agents. In this article, I review the current dilemmas we face, suggest key clinical and biological research priorities, and conclude that we need to be brave enough to admit our present shortcomings, and then perhaps adopt a more patient-focused, individualized approach to anaemia management.
Goldsmith
David
D
D000740:Anemia / Q000139:chemically induced* / Q000188:drug therapy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D006397:Hematinics / Q000009:adverse effects*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D015996:Survival Rate
D006397:Hematinics; D006454:Hemoglobins